Predictors and Consequences of Serious Adverse Events in Patients Treated With Thrombolysis: A Prespecified Secondary Analysis of the AcT Trial

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Background: With the increasing use of tenecteplase, it is important to understand its safety compared with alteplase. We aimed to determine the incidence, predictors, and functional impact of serious adverse events (SAEs) in patients treated with alteplase versus tenecteplase. Methods: This is a post hoc analysis of the AcT (Alteplase Compared to Tenecteplase) trial, a phase 3 multicenter randomized controlled trial that randomized 1577 ischemic patients with stroke (2019–2022) into tenecteplase versus alteplase presenting P =0.002) and higher endovascular treatment rates (50.2% versus 29.2%; P <0.001) than those without SAEs. Nervous system disorders were the most common SAE (58.2%), including stroke worsening (26.7%) and intracranial hemorrhage (25%). No significant differences were observed in SAE distribution by thrombolytic. Patients with SAEs had higher 90‐day modified Rankin Scale scores (median, 4 versus 2; odds ratio [OR], 3.93 [95% CI, 2.78–5.56]). Independent predictors of SAEs included baseline National Institutes of Health Stroke Scale (per SD increase: OR, 1.2 [95% CI, 1.0–1.5]), large‐vessel occlusion (OR, 1.6 [95% CI, 1.1–2.5]), Alberta Stroke Program Early Computed Tomography Score (per point increase: OR, 0.9 [95% CI, 0.8–1.0]), and cerebral atrophy (per point increase: OR, 1.5 [95% CI, 1.1–1.9]). Conclusions: Our study found no difference between rate or type of SAEs by thrombolytic type, supporting the safety of tenecteplase. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03889249.

This publication has 21 references indexed in Scilit: